Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec
€72 million (above $90 million) in cash at end of June 2013 Important news-flow in Q4 for the two lead programs, TG4010 and Pexa-Vec
Conducting additional analyses of data, continuing to advance clinical trials in other cancers Announcing decision on Phase 3 development in HCC in Q4
Regulatory News: Transgene SA (Paris:TNG) (Euronext Paris: TNG), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer...
Prof. Laurence Zitvogel (MD) and Mr Jean-Luc Bélingard were elected to the board at the AGM held on June 19, 2013
Transaction will grow Platine Pharma Services’ business by 50% Transgene’s shareholding in Platine will be reduced to around 30%
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
